All News

RheumNow Podcast square

Indications Awaiting (12.17.21)

d Jack Cush, MD

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory approvals, plus 3 new cases from rheumatologists.

Read Article
Vaccine2.jpg (keep)

CDC Panel Recommends mRNA COVID Vaccines Over J&J Vaccine

d Jack Cush, MD

The U.S.

Read Article
COVID Test Antibody

Serious Adverse Events Associated with Tocilizumab in COVID-19 Patients

d Jack Cush, MD

Safety analysis of over 1000 adverse events associated with the use of tocilizumab in the treatment of COVID‐19 infection shows both rare expected and some unexpected AE.

Read Article
JAK Safety -- The Lowdown on Infection https://t.co/Mi6EDqP7RE https://t.co/ZVZaXHGHIk

Links:

Dr. John Cush RheumNow ( View Tweet)
Herpes Zoster and Rheumatoid Arthritis: Dr. Akhil Sood ( @AkhilSoodMD) reviews abstract #0981 presented at the #ACR21 annual meeting. https://t.co/M95XQOBWVf https://t.co/X9vaAEAias

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

d Jack Cush, MD

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kay https://t.co/GtMtUh33QE https://t.co/yjJngF25Y4

Links:

Dr. John Cush RheumNow ( View Tweet)
audience learn

Day 4 Report from ACR21

d Jack Cush, MD

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

d Jack Cush, MD

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
Cush ACR learning computer online

Day 2 Report from ACR21

d Jack Cush, MD

This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.

Read Article
Did you know?🤔Immune #aging: 🔖Begins at 20y and accelerates at 50y 🔖Species-specific 🔖The older immune system is restructured (keep that in mind when diagnosing or treating these pts) 🔖Accelerated w/ chemotx, chronic infection etc. @RheumNow #ACR21 https://t.co/bgbN3VKMCw
sheila RHEUMarampa ( View Tweet)
Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care 🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide 🔹🚫significant diff 🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose https://t.co/AYQFXqlubl #ACR21 Abst1288 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Knowledge Bowl at #ACR21 ⭐️In this triad seen in TB arthritis, one can see juxta-articular osteopenia, peripheral osseous erosions, and late joint space narrowing ➡️Phermister's triad @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#volcosporin good ~lupus nephritis added to #MMF but underbelly - side effects like but ?less than #cyclosporin. #FDA update - ⬆️hypertension and nephrotoxicity, infection #ACR21 @RheumNow https://t.co/w5nLLSTlrB

Links:

Janet Pope Janetbirdope ( View Tweet)

#PJP prophylaxis debate at #lupus hub if on #prednisone + immune suppression. #SLE has ⤴️septra side effects. Don’t know right answer. NNT v NNH is unknown. I don’t use it in #SLE. @RheumNow #ACR21 8M212

Janet Pope Janetbirdope ( View Tweet)

ACR Best

ACR21 Best Abstracts - Day 2

d Jack Cush, MD

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Read Article
A worthwhile point: despite historic concerns, in the modern era TNFi can used safely & well in HIV pts 18y follow-up, all pts high CD4 (their starting criteria: CD4>200, VL <60,000) no reported opportunistic infx good arthritis response #ACR21 ABST0965 @RheumNow @CCalabreseDO https://t.co/5pbRg63ubr
David Liew drdavidliew ( View Tweet)
HZV in pts w/ #rheumatic dse by Dr CCMok et al 🔸Prevalence rates of HZV infxn (per 100py): SLE 1.7, RA 0.64, other RDs 0.76 🔸RFs assoc'd w/1st HZV infection 📌#SLE dx, serum albumin, serum creatinine; ⬆lympho/neutro ratio, CYC & Prednisolone use @RheumNow #ACR21 abs0862 https://t.co/TXRmoBBDXK
sheila RHEUMarampa ( View Tweet)
Abst 0562 Ungprasert & colleagues examine hospitalization and resource utilization among patients with #AnkylosingSpondylitis - Prevalence is high - Infection was among the most common reasons for hospitalization (sepsis, pneumonia, UTI) #ACR21 @RheumNow https://t.co/UftoFllE1v
Akhil Sood MD AkhilSoodMD ( View Tweet)
acr_session2.jpeg

Opening Day Report

d Jack Cush, MD

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.